96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects

Porter Danielle P.; Kulkarni Rima; Fralich Todd; Miller Michael D.; White Kirsten L.

首页> 外文期刊>HIV clinical trials >96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects

【24h】

96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects

机译：STaR研究的96周耐药性分析：未经抗逆转录病毒治疗，感染HIV-1的受试者中的rilpivirine / emtricitabine / tenofovir DF与efavirenz / emtricitabine / tenofovir DF对比

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: STaR (GS-US-264-0110) was a 96-week phase 3b study evaluating the safety and efficacy of two single-tablet regimens, rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF) and efavirenz/emtricitabine/tenofovir DF (EFV/FTC/TDF) in treatment-naive, HIV-1-infected subjects.

机译：背景：STaR（GS-US-264-0110）是一项为期96周的3b期研究，评估了两种单片治疗方案的安全性和有效性：利比韦林/恩曲他滨/替诺福韦DF（RPV / FTC / TDF）和依非韦伦/ emtricitabine /替诺福韦DF（EFV / FTC / TDF）用于未接受过HIV-1感染的初治患者。

著录项

来源
《HIV clinical trials》 |2015年第1期|共9页
作者
Porter Danielle P.; Kulkarni Rima; Fralich Todd; Miller Michael D.; White Kirsten L.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词
Rilpivirine; Efavirenz; Resistance; E138K; M184V; M184I;

机译：瑞匹韦林;依法韦仑;耐药;E138K;M184V;M184I;

相似文献

外文文献
专利

1. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects [J] . Porter Danielle P., Kulkarni Rima, Fralich Todd, HIV clinical trials . 2015,第1期

机译：STaR研究的96周耐药性分析：未经抗逆转录病毒治疗，感染HIV-1的受试者中的rilpivirine / emtricitabine / tenofovir DF与efavirenz / emtricitabine / tenofovir DF对比
2. Rilpivirine versus efavirenz in hiv-1-infected subjects receiving emtricitabine/tenofovir df: Pooled 96-week data from ECHO and THRIVE studies [J] . NelsonM.R., ElionR.A., CohenC.J., HIV clinical trials . 2013,第3期

机译：接受恩曲他滨/替诺福韦df感染HIV-1的受试者中的Rilpivirine与efavirenz：来自ECHO和THRIVE研究的96周数据汇总
3. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients [J] . White Kirsten L., Kulkarni Rima, McColl Damian J., Antiviral therapy . 2015,第3期

机译：初次接受抗逆转录病毒治疗的患者对Elvitegravir / cobicistat / emtricitabine / tenofovir DF与efavirenz / emtricitabine / tenofovir DF的抵抗力在144周的耐药性分析
4. Changing Patterns of NRTI Resistance in an Inner City Population taking Tenofovir DF over Two Years [C] . H. Fernandes, D. Chew, E. Albanese International AIDS Conference . 2004

机译：两年内，在内城市人口中改变NRTI抗性模式
5. Cost effectiveness analysis of abacavir/lamivudine versus tenofovir/emtricitabine combination therapy as part of highly active antiretroviral therapy in treatment naive HIV-infected patients. [D] . Giguere, Pierre. 2010

机译：阿巴卡韦/拉米夫定与替诺福韦/恩曲他滨联合疗法作为高活性抗逆转录病毒疗法治疗未受HIV感染的患者的成本效益分析。
6. 537STaR: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF has Similar Efficacy and is Well-Tolerated Compared to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Females at Week 96 [O] . Catherine Creticos, Cynthia Brinson, Cheryl Mcdonald, 2014

机译：537STaR：第96周时单用药方案的利必韦林/恩曲他滨/替诺福韦DF与依非韦伦/恩曲他滨/替诺福韦DF疗效相似且耐受性好
7. STAR Study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-naïve adults [O] . C Cohen, D Wohl, J Arribas, 2012

机译：STAR研究：单一片剂方案恩曲他滨/利比韦林/替诺福韦DF在不接受ART的成人中不逊于依非韦伦/恩曲他滨/替诺福韦DF

96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects

摘要

著录项

相似文献

相关主题

期刊订阅